XENE241220P47500
- 0.00
- 0.000.00%
Xenon Pharmaceuticals Newsroom
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $56
TD Cowen Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating
Stifel Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $62
A Quick Look at Today's Ratings for Xenon Pharmaceuticals(XENE.US), With a Forecast Between $53 to $60
Xenon Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham
Xenon Pharmaceuticals: Strategic Advancements and Promising Clinical Developments Earn a Buy Rating
J.P. Morgan Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating
Raymond James Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Cuts Target Price to $50
Stifel Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $62
H.C. Wainwright Initiates Xenon Pharmaceuticals(XENE.US) With Buy Rating, Announces Target Price $53
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $55
Press Release: Xenon Expands Leadership Team With Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Buy Rating Affirmed: Xenon Pharmaceuticals' Promising Clinical Trials and Pipeline Advancement
Xenon Pharmaceuticals Analyst Ratings
RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target
Citi: Maintains Xenon Pharmaceuticals (XENE.US) rating, adjusted from buy to buy rating, and adjusted the target price from $62.00 to $60.00.
Xenon Pharmaceuticals Analyst Ratings
Citigroup Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Wedbush: Maintaining the Xenon Pharmaceuticals (XENE.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $51.00 to $50.00.